Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma
JAMA Oncology · 01.04.2024 · 10 (4) · 456
DOI: 10.1001/jamaoncol.2023.6552 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Oncology, erschienen am 01.04.2024. Verfasst von Jinxuan Dai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Key Laboratory of Oncology (Guilin Medical University), Education…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Induction chemotherapy plus concurrent chemoradiotherapy is recommended for locoregionally advanced nasopharyngeal carcinoma but is associated with higher rates of acute toxic effects and low compliance. Evidence on de-escalating treatment intensity after induction chemotherapy is limited.
Objective
To assess if radiotherapy was noninferior to chemoradiotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Design, Setting, and Participants From April 2015 to March 2018, a multicenter, open-label, randomized, noninferiority, phase 3 trial was conducted at 5 Chinese hospitals. A total of 383 patients aged 18 to 70 years with an untreated histologically confirmed nonkeratinizing tumor, Karnofsky performance status score not worse than 70, proper organ function, and stage III to IVB nasopharyngeal cancer were enrolled. Data were analyzed from April 2023 to June 2023.
Interventions
Patients were assigned randomly. Both groups received 3 cycles of induction chemotherapy consisting of intravenous administration (on day 1) of cisplatin at 60 mg/m 2 and docetaxel at 60 mg/m 2 and continuous intravenous infusion (from day 1 to day 5) of daily fluorouracil (600 mg/m 2 ), repeated every 21 days. Subsequently, the patients received radiotherapy alone (induction chemotherapy in combination with radiotherapy [IC-RT] group) or concomitant cisplatin (30 mg/m 2 /week) with radiotherapy for 6 to 7 weeks (induction chemotherapy combined with chemoradiotherapy [IC-CCRT] group). Main Outcomes and Measures The primary end point was 3-year progression-free survival (time from the initiation of therapy until the first indication of disease progression or death), with a noninferiority margin of 10%. The secondary end points included overall survival, locoregional failure-free survival, distant metastasis-free survival, response rate, and toxic effects.
Results
A total of 383 patients (median [range] age, 48 [19-70] years; 100 women [26%]). Median follow-up time was 76 months (IQR, 70-89 months). The 3-year progression-free survival was 76.2% and 76.8% in the IC-RT (n = 193) and IC-CCRT groups (n = 190), respectively, in the intention-to-treat population, showing a difference of 0.6% (95% CI, –7.9% to 9.1%; P = .01 for noninferiority). Identical outcomes were reported in the per-protocol population. The incidence of grade 3 to 4 short-term toxic effects in the IC-RT group was less than the IC-CCRT group. No differences were observed in late toxic effects. Conclusions and Relevance The results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. Trial Registration ClinicalTrials.gov Identifier: NCT02434614
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Key Laboratory of Oncology (Guilin Medical University), Education Department of Guangxi Zhuang Autonomous Region, Guilin, China.
- Department of Radiation Oncology, Wuzhou Red Cross Hospital, Wuzhou, China.
- Department of Radiation Oncology, Lingshan People's Hospital, Lingshan, China.
- Department of Radiation Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
- Department of Radiation Oncology, Mizhu Hospital of Guangxi Zhuang Autonomous Region, Affiliated Minzu Hospital of Guangxi Medical University, Nanning, China.
Zitieren
APA
Dai, J., Zhang, B., Su, Y., Pan, Y., Ye, Z., Cai, R., Qin, G., Kong, X., Mo, Y., Zhang, R., Liu, Z., Xie, Y., Ruan, X., & Jiang, W. (2024). Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma. JAMA Oncology, 10(4), 456. https://doi.org/10.1001/jamaoncol.2023.6552
Vancouver
Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, et al. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma. JAMA Oncology. 2024;10(4):456. doi:10.1001/jamaoncol.2023.6552
BibTeX
@article{Dai2024,
author = {Dai, Jinxuan and Zhang, Bin and Su, Yixin and Pan, Yufei and Ye, Zhenkai and Cai, Rui and Qin, Guanjie and Kong, Xiangyun and Mo, Yunyan and Zhang, Rongjun and Liu, Zhengchun and Xie, Yuan and Ruan, Xiaolan and Jiang, Wei},
title = {Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma},
journal = {JAMA Oncology},
year = {2024},
volume = {10},
number = {4},
pages = {456},
doi = {10.1001/jamaoncol.2023.6552}
}
EUVIMED